Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Hesse, Elisabeth M. ; Shimabukuro, Tom T. ; Su, John R. ; Hibbs, Beth F. ; Dooling, Kathleen L. ; Goud, Ravi ; Lewis, Paige ; Ng, Carmen S. ; Cano, Maria V.
• Description:
  Recombinant zoster vaccine (RZV; Shingrix), an adjuvanted glycoprotein vaccine, was licensed by the Food and Drug Administration (FDA) and recommended by the Advisory Committee on Immunization Practices for adults aged ≥50 years in October 2017 (1). The previously licensed live-attenuated zoster vaccine (ZVL; Zostavax) is recommended for adults aged ≥60 years. RZV is administered intramuscularly as a 2-dose series, with an interval of 2-6 months between doses. In prelicensure clinical trials, 85% of 6,773 vaccinated study participants reported local or systemic reactions after receiving RZV, with approximately 17% experiencing a grade 3 reaction (erythema or induration >3.5 inches or systemic symptoms that interfere with normal activity). However, rates of serious adverse events (i.e., hospitalization, prolongation of existing hospitalization, life-threatening illness, permanent disability, Congenital anomaly or birth defect, or death) were similar in the RZV and placebo groups (2). After licensure, CDC and FDA began safety monitoring of RZV in the Vaccine Adverse Event Reporting System (VAERS) (3). During the first 8 months of use, when approximately 3.2 million RZV doses were distributed (GlaxoSmithKline, personal communication, 2018), VAERS received a total of 4,381 reports of adverse events, 130 (3.0%) of which were classified as serious. Commonly reported signs and symptoms included pyrexia (fever) (1,034; 23.6%), injection site pain (985; 22.5%), and injection site erythema (880; 20.1%). No unexpected patterns were detected in reports of adverse events or serious adverse events. Findings from early monitoring of RZV are consistent with the safety profile observed in prelicensure clinical trials.
• Subjects:
  Adverse Drug Reaction Reporting Systems Aged Aged, 80 And Over Female Full Report Herpes Zoster Vaccine Humans Male Middle Aged Product Surveillance, Postmarketing Vaccines, Synthetic

  More +
• Source:
  MMWR Morbidity Mortal Weekly Rep. 68(4):91-94
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm6804a4
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  30703077
• Pubmed Central ID:
  PMC6400583
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  4 pdf pages
• Volume:
  68
• Issue:
  4
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:028f8a6a06958d4b6aba85e53c0f4aba197965b3c8556f8fa66398e2b8a373bbbe130f7a19576c6fc09240f821e710e091361e05d308512900f82206fadf3320
• Download URL:
  https://stacks.cdc.gov/view/cdc/76390/cdc_76390_DS1.pdf
• File Type:
  [PDF - 180.36 KB ]